Edward Hospital

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Atrial fibrillation2 trials
• Aortic aneurysm1 trial
• Bladder cancer1 trial
• Stroke1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 32 trials

Status

• Recruiting2 trials
• Active, not recruiting1 trial
• Completed1 trial
• Terminated1 trial

Lead sponsor

• Boston Scientific Corporation2 trials
• Cook Research Incorporated1 trial
• Gilead Sciences1 trial
• Pfizer1 trial

Running trials

• Recruiting

  Zenith® Fenestrated+ Clinical Study

  NCT04875429· Cook Research Incorporated· Source

  Contact: George Pontikis, MD

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

  NCT04165317· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Aortic aneurysm1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

  NCT03795298· Boston Scientific Corporation· Source

• Terminated

  Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497· Boston Scientific Corporation· Source